With Amgen dropping after hours and Merck, Celgene and others reporting earnings on Thursday, how should you game health care?
Amgen reported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.
Stocks finished lower after well-known banking analyst Dick Bove downgraded his rating on Wells Fargo.
Stocks advanced Wednesday as investors were encouraged by a few earnings reports, including Morgan Stanley, Yahoo and SanDisk. The VIX, widely considered the best gauge of fear in the market, dropped to just above 20.
Stocks opened lower Wednesday as a raft of companies beating earning estimates but failed to impress investors.
Earnings season continues in earnest Wednesday, as we roll on with a week that will ultimately see 25 percent of the S&P 500 report their quarterly numbers.
Biotech investors will be closely watching results from Amgen on Wednesday. How should you game this stock into earnings?
Stocks rallied Monday, after a wobbly start, as investors were optimistic about the slew of earnings ahead.
Stocks rallied Monday, after a wobbly start, as techs dragged but investors were optimistic about the slew of earnings ahead.
In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.
Stocks moved higher Monday, after a wobbly start, as techs dragged but investors were optimistic about the slew of earnings ahead.
Stocks continued to struggle on Friday. Could this be the beginning of a real market correction? Mike Rubino, president of Rubino Financial, and Paul Schatz, president of Heritage Capital, discussed how investors should position their portfolios for the end of the third quarter.
The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.
Stocks hit new highs for 2009 after the weak dollar sent oil, gold and other commodities sharply higher.
When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
Stocks snapped their winning streak Thursday after soaring this week to new highs for the year.
Stocks got a quick pop Thursday from the Philadelphia Federal Reserve report on regional manufacturing but turned negative as General Electric dragged on the Dow.
Stocks got a quick pop Thursday from the Philadelphia Federal Reserve report on regional manufacturing but the gains began to fade as weakness nagged at the market. United Technologies, Bank of America and General Electric led the Dow.
Stock index futures showed relatively little reaction to the mixed economic reports out before the bell.
It seems three biotech stocks may be poised to break out. Find out which stocks to put on your radar right now.